Cost-effectiveness of vantrelimab versus pembrolizumab in PD-L1-high NSCLC (Germany)

EVP-0003HEOR studyVantrexaAnalysisRisk lowSponsor: Company

NPDr. Nikolai PetrovHead of Evidence Generation & HEOR

Evidence gap: Health-economic value in EU markets
Objective: SO-VTX-01
Research question: What is the ICER of vantrelimab from a German statutory-insurance perspective?
Design: Partitioned-survival model
Investigator: —
Institution: —
Countries: Germany
Data source: VOYAGE-1 + German cost inputs
Submitted: 20 Nov 2025
Approved: 12 Jan 2026 (53 days)
Contract / ethics: ExecutedEthics not required
Budget / spend: $198k of $240k
83%
Enrolment: n/a

Workflow

Evidence-generation workflow (PRD §17); Rejected is a terminal branch from any review stage.

Current stageAnalysisDemo action — not persisted

Review stages passed, derived from workflow position

Study milestones from CTMS (INT-06)

Milestone	Due	Completed	Status	Evidence / note	Late days
Model validated	30 Jun 2026	08 Jul 2026	Completed	Evidence missing	+8
Manuscript submitted	15 Aug 2026	—	At risk	Statistical review delayed	+31

Insights citing the evidence gap "Health-economic value in EU markets"

No linked insights

No related risks

No dependencies recorded

No audit events for this record

Create, update, approve and export events appear here with user, timestamp, previous and new values.